|Year : 2019 | Volume
| Issue : 2 | Page : 93-100
Prevention of atopic dermatitis: Etiological considerations and identification of potential strategies
John C Su1, Adrian J Lowe2
1 Department of Dermatology, Monash University, Eastern Health, Box Hill; Department of Paediatrics, University of Melbourne; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Melbourne, Australia
2 Murdoch Children's Research Institute, Royal Children's Hospital, Parkville; Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
|Date of Web Publication||29-Mar-2019|
Prof. John C Su
Level 2/5 Arnold St., Box Hill 3128, Victoria
Source of Support: None, Conflict of Interest: None
Research during the last decade has given many new insights into factors contributing to the development and evolution of atopic dermatitis (AD). Factors identified include skin barrier defects, proinflammatory predispositions, anomalies in the microbiome, and some environmental influences. There is now the possibility of personalizing therapy and potentially, of disease prevention. However, discerning the respective roles of early factors leading to AD development is complex. Stringent analysis for confounders must precede attribution of causality to any factor. This review examines current understandings of AD pathogenesis and related research approaches in AD primary prevention.
Keywords: Barrier, eczema, march, microbiome, probiotics
|How to cite this article:|
Su JC, Lowe AJ. Prevention of atopic dermatitis: Etiological considerations and identification of potential strategies. Indian J Paediatr Dermatol 2019;20:93-100
|How to cite this URL:|
Su JC, Lowe AJ. Prevention of atopic dermatitis: Etiological considerations and identification of potential strategies. Indian J Paediatr Dermatol [serial online] 2019 [cited 2019 Jul 19];20:93-100. Available from: http://www.ijpd.in/text.asp?2019/20/2/93/255193
| Introduction|| |
The burden of atopic dermatitis (AD) is high. Moderate-to-severe childhood AD shows greater family impact than Type 1 diabetes. Average annual personal costs have been estimated from Aus$330-1255/year (Australia, 1996) to US$274/month (USA, 2016)., Annual population cost of eczema has been estimated to be US$5 billion in the United States.
In Australia, 1 in 3 infants develop AD in infancy. Of these, East-Asian infants, especially those of recent immigrants, are at particular risk compared with those of nonAsian parents, despite lower parental rates of allergy. Eczema tops all skin diseases for years lived with disability and disability-adjusted life years. About 90% of AD patients experience daily itch and two-thirds have sleep disturbance., Comorbidities include other atopic disorders, infections, obesity, growth disturbance, attention deficit hyperactivity disorder and mental health disease, speech disorder, headaches, organ-specific autoimmunity, and anemia. Persistent disease is particularly costly and appears to correlate with later onset, preexisting duration, and severity. However, persistent, early-onset (and more severe) disease appears to particularly herald possible future food and respiratory allergy, with their attendant burdens.,,
Preventative medicine aims to prevent illness and its complications. Primary prevention seeks to prevent disease onset, by removing pathogenic factors, counteraction (e.g., immunization), or general health promotion. Secondary prevention seeks early detection of disease onset/symptoms to arrest, reverse, and mitigate disease processes and progression (e.g., by screening). Tertiary prevention seeks to reduce impairments and disabilities of preexisting disease (e.g., prevention of complications) or to optimize patient adjustment, thereby minimizing biopsychosocial burden and handicap.
Two further categories of prevention address the very early life; these precede and overlap with primary prevention. Primal prevention refers to affective and physical interventions 'from conception to first anniversary' that may ultimately benefit later health, possibly through epigenetic mechanisms. Primordial prevention refers to preventing the development of risk factors themselves. This article discusses the current understanding of potential strategies for primary AD prevention, including researched primal and primordial strategies.
| Pathogenic Factors in Atopic Dermatitis|| |
AD pathogenesis involves genetic and environmental factors. These include the skin barrier, an atopic diathesis, the microbiome, and other factors involved in the environment-gene interplay.
Barrier disruption may result from gene mutation and/or environmental factors.
At least 31 risk loci for AD are identified, many with roles in barrier development and maintenance as well as immunity., Filaggrin null mutations occur in 40% of persons with moderate-severe AD compared with 10% of healthy Caucasians; loss-of-function mutations confers a three-fold AD risk and are more commonly associated with earlier, more severe disease. Intragenic copy number variations also contribute dose-dependently to barrier defect. Claudin-1, involucrin, loricrin, desmoglein 1, desmoplakin, LEKTI, and ceramides are also associated with AD risk.,,,, Barrier protein modifiers in AD include Toll-like receptors (TLRs) and alarmins.,,,
Impaired skin barrier enables the chemical induction of Th1 and Th2 responses. An initial “nonIgE≵-infantile phase of eczema may progress to a sensitized “IgE-associated” phase. AD may remit, progress to respiratory allergy (the “atopic march≵), and/or develop auto-allergic self-sensitization to self-proteins. Initial skin inflammation relates to innate immunity, whereas later (e.g., respiratory) allergy requires sensitization and adaptive immunity.,,, AD may thus be stratified by the age of onset, endophenotype, and biomarker profiles to help personalize treatment and potential prevention strategies.
Various factors affect the skin barrier such as low humidity, itching, age, and water, which can cause filaggrin proteolysis. High pH may damage the acid mantle, modify protein expression, and alter protease activity.
Primary (genetic) immunological diatheses may be potential targets for primary prevention and therapy. These may affect T-cell signaling, cytoskeletal remodeling, cytokine signaling, T-cell repertoire, tolerance failure, metabolic disturbance, and mast cell deregulation. The role of nonimmunological factors such as neuropeptides, neurotrophins, and growth factors is unclear.
The microbial diversity hypothesis proposes that life-style delimited microbe-host interaction deprives immunological training leading to Th2 skewing and AD., Whereas antibiotic use and cat exposure in the setting of impaired skin barrier appear to increase AD risk,,, reduced AD has been related to exposure to helminths, early day-care, endotoxin, unpasteurized farm milk, and animals. Nonpathogenic microbes, possibly gastrointestinal, may cause antigen-presenting cells to mature into a pro-regulatory form, APCregs, driving Treg cells production.,,,
Skin microbiome may also affect AD development. Reduced microbial diversity before AD onset and reduction of AD in infants with early commensal Staphylococcus have been observed. TLRs in AD may modify the recognition of microbial molecular patterns, thus influencing adaptive immunity and percutaneous sensitization. In AD, keratinocyte-derived antimicrobial peptides (AMPs) may be reduced and this may also increase S. aureus, as may AD cytokines and biofilms. Conversely, coagulase-negative Staphylococcus may produce strain specific AMPs that synergize with human LL-37 to kill S. aureus; such commensals may be reduced in AD.
Vitamin D may also play a role in AD pathogenesis, but AD associations with maternal Vitamin D supplementation, cord blood levels, and serum levels are inconsistent. Vitamin D supplementation may potentially improve severe pediatric AD. Its stimulation of cathelicidin and beta-defensin may enhance filaggrin expression and complement its activity in stimulating TLRs, altering keratinocyte differentiation, suppressing dendritic cell maturation, inhibiting Th1 cell proliferation, attenuation of Th2 immunity and inhibiting B-cell function. The relevance of this for AD prevention is unclear.
Itch is a sign of AD but may also play a role in pathogenesis. IL-31 can cause itch and can be induced by S. aureus superantigens and Th2-type cell stimulation. IL-31RA1 receptor is found on IL-31RA1/TRPV1/TRPA1 cutaneous C-fiber and dorsal root ganglia neurons. However, itch-related TRPV1, TRPV3, TRPV4, and TRPA1 channels on keratinocytes and sensory nerve fibers can also be directly triggered by thermal, mechanical, and chemical cutaneous stimuli. These include textile fibers with mean diameters >30–32 μ. Effects of physical and chemical microclimate stimuli on cutaneous inflammation are, to date, largely unstudied, but may have relevance for both primary and tertiary disease prevention.
| Prevention-Theory and Evidence|| |
Xerosis and increased transepidermal water loss may result from defects of epidermal structural and protective proteins (e.g., filaggrin and S-100 proteins), decreased extracellular ceramides, altered stratum corneum pH, or overexpression/defects of chymotryptic enzymes, thus allowing increased penetration of skin by allergens and microbes. Macharia et al. found that fewer patients developing AD use petrolatum jelly than healthy infants, but data from prospective studies have only appeared in the past 4 years.
The way emollients restore skin barrier is incompletely understood and molecular effects may be more complex than previously thought. Recent studies revealed cytokine changes following moisturization (i.e., up-regulation of key AMPs and innate genes, improved expression of epidermal differentiation markers, improved skin pH, and altered skin microbiome)., Studies comparing efficacies of moisturizers in AD (of both affected and healthy skin) are few; apparent differences in efficacy for the prevention and delay of AD relapse have been attributed to respective effects on skin barrier repair. Four published studies on barrier enhancement for AD onset prevention are discussed below, using different moisturizers.
After showing the feasibility and safety of emollient use in 22 infants from the age of 3 weeks to 6 months, an American-British trial randomized 124 high-risk babies to either a treatment arm of at least daily full-body moisturizer starting from 3 weeks of age (allowing parents to decide from a number of different emollients) or a no emollient control arm. Infants were followed for 6 months. A relative risk reduction of 50% for development of AD was found in the treatment arm, with no difference in adverse effects. An extension of this protocol (BEEP) is underway, studying in 1400 infants, the effect of this intervention on the primary outcome of AD at 24 months of age. The interventions used for the 1st year of life comprise Doublebase Gel and Diprobase cream, which both do not have sodium lauryl sulphate.
In a multi-center Norwegian study of 56 infants with xerosis, a similar reduction was observed in the prevalence of dry skin at 6 months among the 24 infants managed proactively by frequent oil baths (2–4 to 5–7 times a week) and fatty face cream moisturization (skin normalized in 75% and only 4% developed AD). This compared favorably with an observation-only cohort (37.5% normalized, 19% developed AD).
A prospective, randomized, controlled, Japanese study of 118 neonates showed 32% lower cumulative incidence of AD at 32 weeks for infants treated with daily emulsion-type moisturizer than for the controls (P = 0.12 log-rank test). They did not find a difference in allergic sensitization to egg white between the two groups; this was not explained.
By comparison, for our own study, we chose a ceramide-based emollient, Epiceram, which has physiological proportions of ceramides, cholesterol, and free fatty acids, a pH of 5, and shown previously by us to be safe for neonatal use. High-risk infants were randomized 1:1 into an observation arm, and a treatment arm comprising twice daily whole-body application of Epiceram (approximately 6 g), starting within 3 weeks of life, for 6 months. We found a trend to reduced AD risk at 6 and 12 months with intention-to-treat analysis. Per protocol analysis, only looking at infants using treatment at least 5 days a week, showed a significant reduction in food sensitization at 12 months (0% of 21 vs. 19% of 36; P = 0.04); treated infants who developed sensitization, started treatment relatively late. Beneficial effects, therefore, appeared to persist beyond the treatment period. The benefits of moisturization in the treatment group may have been underestimated because 39% of controls vs. 18% of the treatment group also used nonstudy-related emollients for an average of 3 or more days a week.
Longer-term studies and those comparing specific and different moisturizers, including virgin coconut oil and those with prebiotics, could be beneficial. Studying the role of moisturizers on secondary prevention alongside other topical measures like TCIs would also be valuable.
GI-directed measures: Prebiotics and probiotics, formula, and breastfeeding
Given the observed dysbiosis observed in AD, it has been suggested that probiotics may have benefits for both prevention and treatment of AD. Probiotics are live microorganisms that may confer benefits to the host, whereas prebiotics are nondigestible carbohydrates that stimulate the growth of probiotic bacteria in the intestines. Synbiotics refer to combinations of both these categories.
Therapeutic benefits of probiotics have not been consistently demonstrated in studies of childhood and adult AD. Possible effects of probiotics that may facilitate AD prevention includes increased intestinal microflora diversity, reduced fermentation products, inhibited S. aureus attachment, Th2 response inhibition, Th1 response stimulation, regulatory T-cell upregulation, and skin barrier enhancement. Some early reports reported a small increase in adverse effects like recurrent wheezing/bronchitis with probiotics.
Recent meta-analyses of perinatal use of probiotics suggest an associated reduction of AD incidence of 20%–24% and a preventative role, especially when given during the late antenatal period (last 2 weeks of pregnancy) and first 3–6 months of life. Long-term effects are unclear. The pooled relative risk ratio of AD has been suggested to be 0.74 (95% confidence interval (CI): 0.67, 0.82), but this is limited by the heterogeneity of studies. What is most unclear for probiotics are the exact identity of the most beneficial strain(s), the ideal timing of administration, the optimal dose, the preferred mode of delivery, and effects of concurrent prebiotics.,
Some of these effects may be strain specific and modulated by TLRs. Meta-analyses of Pelucchi et al. and Panduru (2015) found a possible 20%–24% reduction in the likelihood of developing AD with prenatal and postnatal probiotics use, particularly for Lactobacillus and Bifidobacterium, but consistent longer-term benefits have not been established.
The ProPACT study, for example, showed nonresponse to probiotics among children with divergent microbiota and overrepresentation of Bifidobacterium dentium, but a positive response in others, a finding possibly suggesting an important relationship between the timing of exposures and benefits of specific microbiota constitutions; this will need further study. They found a reduced Th22 cell proportion following perinatal (36 weeks gestation until 3 months postnatal) maternal probiotic supplementation as follows: a combination of Lactibacillus rhamnosus GG, Bifidobacterium animalis ctis Bb-12, and Lactobacillus acidophilus 5. Th22 cells were reduced in children who did not develop AD on probiotics and increased in children who developed AD. With an overall relative risk of 0.43 (P = 0.025) for probiotics, mediation analysis attributed a RR of 0.73 to the Th22 reduction, and a RR of 0.59 to other pathways. Generation of CD4+ FoxP3+ Tcells by multi-strain probiotics has been described in mice with preexisting AD.
Similarly benefits of prebiotics in early infancy have been suggested by meta-analyses of early life data, (up to 32% AD reduction for a galacto-oligosaccharide and fructo-oligosaccharide combination, according to Osborn and Sinn), but long-term data are lacking. Intrinsic infantile microbiota may affect the response.
Synbiotics are mixtures of prebiotics and probiotics. Two perinatal primary prevention studies have looked at the effects of galacto-oligosaccharides administered together with probiotics, showing a pooled relative risk compared with placebo of 0.44 (95% CI: 0.11, 1.83. P =0.26). As such, while the available evidence is consistent with a potentially important preventive effect, it is too early to advocate this as a strategy.
The effect of hydrolyzed formula on AD prevention is contested. The German GINI study suggested a reduced AD cumulative incidence relative risk (0.75, 95% CI: 0.59, 0.96) for infants fed partial whey hydrolysate; extensive casein hydrolysate reduced cumulative incidence (risk ratio: 0.60 95% CI: 0.46, 0.77) and cumulative prevalence (Odds ratio: 0.42 95% CI: 0.23, 0.79). However, a recent rigorous systematic review failed to demonstrate the effectiveness of hydrolyzed formula for the prevention of AD.,
There is some evidence for a link between breastfeeding (which also contains probiotics and prebiotics) and reduced AD incidence, but this is still contested., However, there is no support for maternal dietary allergen avoidance during pregnancy.
Macro- and microenvironment
There is growing interest in diverse, environmental conditions, as potential risk factors for AD. Skin is protected by various mechanisms, including its acid mantle, which can be affected by water hardness(32), through increased surfactant deposition on skin, and possibly by chlorine. A recent study of 53,000 children from the Danish National Birth Cohort looking at the prevalence of physician diagnosed AD from parental interviews at 6 and 18 months suggested an overall AD prevalence of 15%, ranging from 13.5% in regions with the softest water to 17.1% in those with the hardest domestic water. Relative prevalence increased by 5% per 5-degree increase in water hardness. Independently, AD relative prevalence for babies born in fall was 24% compared with 18% for those born in winter. This study presents compelling evidence to further examine the effects of the macroenvironment on the development of AD although the respective importance of water content, climate, sunlight, and Vitamin D is not clear.
Studies on the skin microenvironment on the management of AD are very few. Many teachings regarding clothing in AD have been based on anecdotal experience and dated, poorly conducted studies. Our recent publication on the effects of superfine merino wool on infants with mild-to-moderate AD suggested a beneficial effect of superfine wool compared with standard clothing, thus challenging previously generalized beliefs regarding adverse effects of wool on the skin. Changes in textile technology and understandings of both fiber properties and skin physiology compel our further examination of the skin microenvironment and its effects on AD development and response. By contrast, another study failed to demonstrate advantages of adding in silk clothing to standard care of AD.
Reduction of AD has been associated with breast feeding promotion in one intervention trial and numerous observational studies, with biologic plausibility.,, However, this is contested by a sizeable number of other cohort studies, some of which suggest increased AD risk with prolonged or exclusive breastfeeding.
A systematic review and meta-analysis of controlled studies (n = 9, including four randomized controlled studies) examining Vitamin D supplementation and AD symptoms suggested a higher mean difference in AD symptoms after supplementation (mean-5.81, 95% CI: −9.03, −2.59) in established AD. However, the protective effect of Vitamin D on AD development is both supported, and refuted.,,,
An association between proper observation of vaccination schedules, particularly with oral live-attenuated poliovirus and bacillus Calmette-Guerin, and reduced atopic disease incidence has been described, but it lacks confirmation. There is little support for the utility of systemic and cutaneous allergen avoidance in primary prevention of AD; conversely there are potential adverse effects of allergen avoidance on the development of immunological tolerance and general infant health to be considered. An appraisal of 7 RCTs examining dust mite avoidance for the primary prevention of AD in high-risk infants have failed to demonstrate any benefit. The role of antihistamines is limited and given their neurological adverse effects and the limited evidence for any pathogenic role of histamine in AD, they are not recommended in practice.
Long-chain n-3 fatty acids have shown effects in the therapy of AD and in the reduction of allergic sensitization., Reduced prevalence of IgE-mediated AD in offspring of pregnant women treated with n-3 fatty acids is reported in two of five human studies. Studies in fecund mice suggest that changes in offspring microbiome may contribute to the prevention of anaphylaxis. In a separate mouse study, B-carotene and lycopene were reported to prevent the induction by a low zinc/magnesium diet of AD-like changes in mice. A summary of key AD prevention strategies with levels of evidence is shown in [Table 1].,
| Conclusion|| |
Primary prevention of AD has the potential to alleviate a huge personal and social disease burden. There is, as yet, inconclusive evidence supporting the role of various interventions, including early infant moisturization, probiotics/prebiotics, Vitamin D supplementation, and long-chain n-3 fatty acids. Larger cohorts using standardized protocols that are followed over longer periods of time are required. At the same time, there remain other potential steps for prevention that may be variably dependent on genotype, endophenotype, clinical phenotype, and specific environmental considerations. With better understanding of AD risk factors and the evident success of more targeted and personalized therapeutic options for AD, the possibility of nuanced primary prevention strategies is becoming increasingly real and thus calls for further research into this area.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: Its impact on the family and financial cost. Arch Dis Child 1997;76:159-62.
Filanovsky MG, Pootongkam S, Tamburro JE, Smith MC, Ganocy SJ, Nedorost ST, et al.
The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr 2016;169:284-90.e5.
Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA, et al.
The burden of atopic dermatitis: Summary of a report for the national eczema association. J Invest Dermatol 2017;137:26-30.
Martin PE, Koplin JJ, Eckert JK, Lowe AJ, Ponsonby AL, Osborne NJ, et al.
The prevalence and socio-demographic risk factors of clinical eczema in infancy: A population-based observational study. Clin Exp Allergy 2013;43:642-51.
Drucker AM. Atopic dermatitis: Burden of illness, quality of life, and associated complications. Allergy Asthma Proc 2017;38:3-8.
Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G, et al.
Itch characteristics in atopic dermatitis: Results of a web-based questionnaire. Br J Dermatol 2009;160:642-4.
Hanifin JM, Reed ML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis 2007;18:82-91.
Silverberg NB, Silverberg JI. Atopic dermatitis: Part I. Clin Dermatol 2017;35:341-3.
Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. J Am Acad Dermatol 2016;75:681-7.e11.
Hill DJ, Heine RG, Hosking CS, Brown J, Thiele L, Allen KJ, et al.
IgE food sensitization in infants with eczema attending a dermatology department. J Pediatr 2007;151:359-63.
Lowe AJ, Angelica B, Su J, Lodge CJ, Hill DJ, Erbas B, et al.
Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age. Pediatr Allergy Immunol 2017;28:384-90.
Lowe AJ, Leung DY, Tang ML, Su JC, Allen KJ. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol 2018;120:145-51.
McKenzie JF, Seabert DM. Prevention: Primary, secondary, and tertiary. In: Boslaugh S, editor. Encyclopaedia of Epidemiology. Vol. 2. Thousand Oaks: SAGE, 2008. p. 838-40.
Porta MS. A Dictionary of Epidemiology. 6th
ed. Oxford: Oxford University Press; 2016.
Brown SJ. Molecular mechanisms in atopic eczema: Insights gained from genetic studies. J Pathol 2017;241:140-5.
Bieber T. Atopic dermatitis and personalized medicine. Allergy 2012;67:1475-82.
Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z. Molecular genetic of atopic dermatitis: An update. Int J Health Sci (Qassim) 2016;10:96-120.
Niehues H, Schalkwijk J, van Vlijmen-Willems IM, Rodijk-Olthuis D, van Rossum MM, Wladykowski E, et al.
Epidermal equivalents of filaggrin null keratinocytes do not show impaired skin barrier function. J Allergy Clin Immunol 2017;139:1979-81.e13.
Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep 2014;14:433.
Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, et al.
Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208.
Koppes SA, Charles F, Lammers L, Frings-Dresen M, Kezic S, Rustemeyer T, et al.
Efficacy of a cream containing ceramides and magnesium in the treatment of mild to moderate atopic dermatitis: A randomized, double-blind, emollient- and hydrocortisone-controlled trial. Acta Derm Venereol 2016;96:948-53.
Kuo IH, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AI, Barnes KC, et al.
Activation of epidermal toll-like receptor 2 enhances tight junction function: Implications for atopic dermatitis and skin barrier repair. J Invest Dermatol 2013;133:988-98.
Can C, Yazıcıoǧlu M, Gürkan H, Tozkır H, Görgülü A, Süt NH, et al.
Lack of association between toll-like receptor 2 polymorphisms (R753Q and A-16934T) and atopic dermatitis in children from Thrace region of Turkey. Balkan Med J 2017;34:232-8.
Salpietro C, Rigoli L, Miraglia Del Giudice M, Cuppari C, Di Bella C, Salpietro A, et al.
TLR2 and TLR4 gene polymorphisms and atopic dermatitis in Italian children: A multicenter study. Int J Immunopathol Pharmacol 2011;24:33-40.
Nygaard U, van den Bogaard EH, Niehues H, Hvid M, Deleuran M, Johansen C, et al.
The “Alarmins” HMBG1 and IL-33 downregulate structural skin barrier proteins and impair epidermal growth. Acta Derm Venereol 2017;97:305-12.
Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 2013;70:3-11.
Saunders SP, Moran T, Floudas A, Wurlod F, Kaszlikowska A, Salimi M, et al.
Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J Allergy Clin Immunol 2016;137:482-91.
De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: A disease caused by innate immune defects? J Invest Dermatol 2009;129:14-30.
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al.
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016;138:336-49.
Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017;139:S65-76.
Bieber T, D'Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al.
Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol 2017;139:S58-64.
Perkin MR, Craven J, Logan K, Strachan D, Marrs T, Radulovic S, et al.
Association between domestic water hardness, chlorine, and atopic dermatitis risk in early life: A population-based cross-sectional study. J Allergy Clin Immunol 2016;138:509-16.
Lyons JJ, Milner JD. Primary atopic disorders. J Exp Med 2018;215:1009-22.
Bloomfield SF, Rook GA, Scott EA, Shanahan F, Stanwell-Smith R, Turner P, et al.
Time to abandon the hygiene hypothesis: New perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene. Perspect Public Health 2016;136:213-24.
Ierodiakonou D, Garcia-Larsen V, Logan A, Groome A, Cunha S, Chivinge J, et al.
Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: A systematic review and meta-analysis. JAMA 2016;316:1181-92.
Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol 2011;41:1-34.
Tsakok T, McKeever TM, Yeo L, Flohr C. Does early life exposure to antibiotics increase the risk of eczema? A systematic review. Br J Dermatol 2013;169:983-91.
Bisgaard H, Simpson A, Palmer CN, Bønnelykke K, McLean I, Mukhopadhyay S, et al.
Gene-environment interaction in the onset of eczema in infancy: Filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008;5:e131.
Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002;296:490-4.
Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ, et al.
Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17-27.
Rook GA, Brunet LR. Microbes, immunoregulation, and the gut. Gut 2005;54:317-20.
Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010;125:4-13.
Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut-skin axis. Front Microbiol 2018;9:1459.
Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, et al.
Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 2016;165:842-53.
Kennedy EA, Connolly J, Hourihane JO, Fallon PG, McLean WH, Murray D, et al.
Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy Clin Immunol 2017;139:166-72.
Kemény L, Szabó K. Toll-like receptors link atopic march to the hygiene hypothesis. J Invest Dermatol 2013;133:874-8.
Bieber T, Novak N. Pathogenesis of atopic dermatitis: New developments. Curr Allergy Asthma Rep 2009;9:291-4.
Di Domenico EG, Cavallo I, Bordignon V, Prignano G, Sperduti I, Gurtner A, et al.
Inflammatory cytokines and biofilm production sustain Staphylococcus aureus
outgrowth and persistence: A pivotal interplay in the pathogenesis of atopic dermatitis. Sci Rep 2018;8:9573.
Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al.
Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus
and are deficient in atopic dermatitis. Sci Transl Med 2017;9. pii: eaah4680.
Wang SS, Hon KL, Kong AP, Pong HN, Wong GW, Leung TF, et al.
Vitamin D deficiency is associated with diagnosis and severity of childhood atopic dermatitis. Pediatr Allergy Immunol 2014;25:30-5.
Tsotra K, Garoufi A, Kossiva L, Gourgiotis D, Tsoukatou T, Katsantoni E, et al.
The impact of Vitamin D supplementation on serum cathelicidin levels and the clinical course of atopic dermatitis in children. Minerva Pediatr 2017. [Epub ahead of print].
Kim G, Bae JH. Vitamin D and atopic dermatitis: A systematic review and meta-analysis. Nutrition 2016;32:913-20.
Zallmann M, Smith PK, Tang ML, Spelman LJ, Cahill JL, Wortmann G, et al.
Debunking the myth of wool allergy: Reviewing the evidence for immune and non-immune cutaneous reactions. Acta Derm Venereol 2017;97:906-15.
Bieber T, Proiss J. Atopic eczema. In: Gaspari AA, Tyring SK, editors. Clinical and Basic Immunodermatology. New York: Springer-Verlag; 2008.
Macharia WM, Anabwani GM, Owili DM. Effects of skin contactants on evolution of atopic dermatitis in children: A case control study. Trop Doct 1991;21:104-6.
Czarnowicki T, Malajian D, Khattri S, Correa da Rosa J, Dutt R, Finney R, et al.
Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer. J Allergy Clin Immunol 2016;137:1091-102.e7.
Glatz M, Jo JH, Kennedy EA, Polley EC, Segre JA, Simpson EL, et al.
Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS One 2018;13:e0192443.
Škerström U, Reitamo S, Langeland T, Berg M, Rustad L, Korhonen L, et al.
Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: A randomized double-blind controlled multicentre clinical trial. Acta Derm Venereol 2015;95:587-92.
Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol 2010;63:587-93.
Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al.
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014;134:818-23.
Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, et al.
Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): Protocol for a randomised controlled trial. Trials 2017;18:343.
Kvenshagen BK, Carlsen KH, Mowinckel P, Berents TL, Carlsen KC. Can early skin care normalise dry skin and possibly prevent atopic eczema? A pilot study in young infants. Allergol Immunopathol (Madr) 2014;42:539-43.
Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al.
Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 2014;134:824-30.e6.
Lowe AJ, Tang ML, Dharmage SC, Varigos G, Forster D, Gurrin LC, et al.
Aphase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates. BMC Dermatol 2012;12:3.
Lowe AJ, Su JC, Allen KJ, Abramson MJ, Cranswick N, Robertson CF, et al.
Arandomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: The PEBBLES pilot study. Br J Dermatol 2018;178:e19-e21.
D'Erme AM, Hohl D. Use of emollient in atopic dermatitis prevention. Dermatol Ther 2016;29:286-7.
Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J Am Acad Dermatol 2014;71:814-21.
Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: No clinical effects of Lactobacillus
GG supplementation. Pediatrics 2008;121:e850-6.
Mansfield JA, Bergin SW, Cooper JR, Olsen CH. Comparative probiotic strain efficacy in the prevention of eczema in infants and children: A systematic review and meta-analysis. Mil Med 2014;179:580-92.
Cuello-Garcia CA, Brożek JL, Fiocchi A, Pawankar R, Yepes-Nuñez JJ, Terracciano L, et al.
Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2015;136:952-61.
Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, et al.
Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: A meta-analysis. Epidemiology 2012;23:402-14.
Panduru M, Panduru NM, Sălăvăstru CM, Tiplica GS. Probiotics and primary prevention of atopic dermatitis: A meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015;29:232-42.
Avershina E, Cabrera Rubio R, Lundgård K, Perez Martinez G, Collado MC, Storrø O, et al.
Effect of probiotics in prevention of atopic dermatitis is dependent on the intrinsic microbiota at early infancy. J Allergy Clin Immunol 2017;139:1399-402.e8.
Rø AD, Simpson MR, Rø TB, Storrø O, Johnsen R, Videm V, et al.
Reduced Th22 cell proportion and prevention of atopic dermatitis in infants following maternal probiotic supplementation. Clin Exp Allergy 2017;47:1014-21.
Shin JH, Chung MJ, Seo JG. A multistrain probiotic formulation attenuates skin symptoms of atopic dermatitis in a mouse model through the generation of CD4+Foxp3+ T cells. Food Nutr Res 2016;60:32550.
Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergy. Cochrane Database Syst Rev 2013;(3):CD006474.
Chang YS, Trivedi MK, Jha A, Lin YF, Dimaano L, García-Romero MT, et al.
Synbiotics for prevention and treatment of atopic dermatitis: A meta-analysis of randomized clinical trials. JAMA Pediatr 2016;170:236-42.
von Berg A, Filipiak-Pittroff B, Schulz H, Hoffmann U, Link E, Sußmann M, et al.
Allergic manifestation 15 years after early intervention with hydrolyzed formulas – The GINI study. Allergy 2016;71:210-9.
Boyle RJ, Ierodiakonou D, Khan T, Chivinge J, Robinson Z, Geoghegan N, et al.
Hydrolysed formula and risk of allergic or autoimmune disease: Systematic review and meta-analysis. BMJ 2016;352:i974.
Lodge CJ, Lowe AJ, Dharmage SC. Do hydrolysed infant formulas reduce the risk of allergic disease? BMJ 2016;352:i1143.
Doherty AM, Lodge CJ, Dharmage SC, Dai X, Bode L, Lowe AJ, et al.
Human milk oligosaccharides and associations with immune-mediated disease and infection in childhood: A systematic review. Front Pediatr 2018;6:91.
Blattner CM, Murase JE. A practice gap in pediatric dermatology: Does breast-feeding prevent the development of infantile atopic dermatitis? J Am Acad Dermatol 2014;71:405-6.
Risch AC. Breastfeeding and atopic dermatitis. Pediatrics 2012;130:e461-2.
Ali SM, Yosipovitch G. Skin pH: From basic science to basic skin care. Acta Derm Venereol 2013;93:261-7.
Danby SG, Brown K, Wigley AM, Chittock J, Pyae PK, Flohr C, et al.
The effect of water hardness on surfactant deposition after washing and subsequent skin irritation in atopic dermatitis patients and healthy control subjects. J Invest Dermatol 2018;138:68-77.
Engebretsen KA, Bager P, Wohlfahrt J, Skov L, Zachariae C, Nybo Andersen AM, et al.
Prevalence of atopic dermatitis in infants by domestic water hardness and season of birth: Cohort study. J Allergy Clin Immunol 2017;139:1568-740.
Su JC, Dailey R, Zallmann M, Leins E, Taresch L, Donath S, et al.
Determining effects of superfine sheep wool in INfantile eczema (DESSINE): A randomized paediatric crossover study. Br J Dermatol 2017;177:125-33.
Thomas KS, Bradshaw LE, Sach TH, Batchelor JM, Lawton S, Harrison EF, et al.
Silk garments plus standard care compared with standard care for treating eczema in children: A randomised, controlled, observer-blind, pragmatic trial (CLOTHES trial). PLoS Med 2017;14:e1002280.
Kramer MS, Chalmers B, Hodnett ED, Sevkovskaya Z, Dzikovich I, Shapiro S, et al.
Promotion of breastfeeding intervention trial (PROBIT): A randomized trial in the republic of Belarus. JAMA 2001;285:413-20.
Garcia-Larsen V, Ierodiakonou D, Jarrold K, Cunha S, Chivinge J, Robinson Z, et al.
Diet during pregnancy and infancy and risk of allergic or autoimmune disease: A systematic review and meta-analysis. PLoS Med 2018;15:e1002507.
Munblit D, Verhasselt V. Allergy prevention by breastfeeding: Possible mechanisms and evidence from human cohorts. Curr Opin Allergy Clin Immunol 2016;16:427-33.
Kim JH. Role of breast-feeding in the development of atopic dermatitis in early childhood. Allergy Asthma Immunol Res 2017;9:285-7.
Oren E, Banerji A, Camargo CA Jr. Vitamin D and atopic disorders in an obese population screened for Vitamin D deficiency. J Allergy Clin Immunol 2008;121:533-4.
Vestita M, Filoni A, Congedo M, Foti C, Bonamonte D. Vitamin D and atopic dermatitis in childhood. J Immunol Res 2015;2015:257879.
Mesquita Kde C, Igreja AC, Costa IM. Atopic dermatitis and Vitamin D: Facts and controversies. An Bras Dermatol 2013;88:945-53.
Bäck O, Blomquist HK, Hernell O, Stenberg B. Does Vitamin D intake during infancy promote the development of atopic allergy? Acta Derm Venereol 2009;89:28-32.
Heimbeck I, Wjst M, Apfelbacher CJ. Low Vitamin D serum level is inversely associated with eczema in children and adolescents in Germany. Allergy 2013;68:906-10.
Wolsk HM, Chawes BL, Litonjua AA, Hollis BW, Waage J, Stokholm J, et al.
Prenatal Vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials. PLoS One 2017;12:e0186657.
Martignon G, Oryszczyn MP, Annesi-Maesano I. Does childhood immunization against infectious diseases protect from the development of atopic disease? Pediatr Allergy Immunol 2005;16:193-200.
Oszukowska M, Michalak I, Gutfreund K, Bienias W, Matych M, Szewczyk A, et al.
Role of primary and secondary prevention in atopic dermatitis. Postepy Dermatol Alergol 2015;32:409-20.
Bremmer SF, Simpson EL. Dust mite avoidance for the primary prevention of atopic dermatitis: A systematic review and meta-analysis. Pediatr Allergy Immunol 2015;26:646-54.
Boulos S, Yan AC. Current concepts in the prevention of atopic dermatitis. Clin Dermatol 2018;36:668-71.
Reese I, Werfel T. Do long-chain omega-3 fatty acids protect from atopic dermatitis? J Dtsch Dermatol Ges 2015;13:879-85.
Miles EA, Calder PC. Can early omega-3 fatty acid exposure reduce risk of childhood allergic disease? Nutrients 2017;9. pii: E784.
Gunaratne AW, Makrides M, Collins CT. Maternal prenatal and/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood. Cochrane Database Syst Rev 2015;(7):CD010085.
Hiragun M, Hiragun T, Oseto I, Uchida K, Yanase Y, Tanaka A, et al.
Oral administration of β-carotene or lycopene prevents atopic dermatitis-like dermatitis in HR-1 mice. J Dermatol 2016;43:1188-92.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.
GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.